{"classes":[{"categories":[{"measurements":[{"comment":"The 95% confidence interval upper limit was not estimable (below the level of detection).","groupId":"OG000","lowerLimit":"41.8","upperLimit":"NA","value":"78.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"295"}],"units":"Participants"}],"description":"EFS was defined as time from registration in this study to the earliest occurrence of any of the following: failure to achieve bone marrow response (defined using the M bone marrow criteria for acute lymphoblastic leukemia (ALL); if M0 to M1 status (blast cells ,5%) was achieved by the end of induction or extended induction, the patient was considered a responder) by day 60, death, relapse at any site, or development of second malignant disease.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients received induction (Course I), consolidation (Course II), interim maintenance (Course III), delayed intensification (Course IV), and long-term maintenance therapy (Course V). Please see the \"Detailed Description\" section for more information.","id":"OG000","title":"Treatment (Pediatric Regimen)"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"Up to 8 years post-registration","title":"Event-free Survival","type":"PRIMARY","unitOfMeasure":"months"}